Ardelyx (ARDX) Receives Daily Media Sentiment Rating of 0.13

News articles about Ardelyx (NASDAQ:ARDX) have been trending somewhat positive on Friday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ardelyx earned a news impact score of 0.13 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.196061143094 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

ARDX stock remained flat at $$5.25 during trading on Friday. The company had a trading volume of 68,168 shares, compared to its average volume of 295,436. Ardelyx has a fifty-two week low of $4.05 and a fifty-two week high of $14.10. The firm has a market cap of $247.54, a P/E ratio of -3.84 and a beta of 0.79.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.60. The firm had revenue of $42.00 million for the quarter, compared to analyst estimates of $6.00 million. equities analysts predict that Ardelyx will post -1.73 EPS for the current fiscal year.

A number of research analysts recently weighed in on the company. BidaskClub downgraded Ardelyx from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded Ardelyx from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald set a $12.00 price target on Ardelyx and gave the stock a “buy” rating in a research note on Monday, February 12th. Leerink Swann reaffirmed an “outperform” rating and set a $13.00 price target on shares of Ardelyx in a research note on Monday, March 19th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Ardelyx in a research note on Thursday, March 15th. Three equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $12.93.

ILLEGAL ACTIVITY WARNING: This article was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

About Ardelyx

Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.

Insider Buying and Selling by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with's FREE daily email newsletter.

Leave a Reply